LT3870578T - Terapiniai junginiai - Google Patents
Terapiniai junginiaiInfo
- Publication number
- LT3870578T LT3870578T LTEPPCT/GB2019/053012T LTGB2019053012T LT3870578T LT 3870578 T LT3870578 T LT 3870578T LT GB2019053012 T LTGB2019053012 T LT GB2019053012T LT 3870578 T LT3870578 T LT 3870578T
- Authority
- LT
- Lithuania
- Prior art keywords
- therapeutic compounds
- therapeutic
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1817193.4A GB201817193D0 (en) | 2018-10-22 | 2018-10-22 | Tetrahydroisoquinoline compounds |
| GBGB1907674.4A GB201907674D0 (en) | 2019-05-30 | 2019-05-30 | Tetrahydroisoquinoline compounds |
| PCT/GB2019/053012 WO2020084300A1 (en) | 2018-10-22 | 2019-10-22 | Therapeutic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3870578T true LT3870578T (lt) | 2023-12-11 |
Family
ID=68393021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/GB2019/053012T LT3870578T (lt) | 2018-10-22 | 2019-10-22 | Terapiniai junginiai |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US12098148B2 (lt) |
| EP (2) | EP4252755A3 (lt) |
| JP (1) | JP7561742B2 (lt) |
| KR (1) | KR20210080474A (lt) |
| CN (1) | CN112996785A (lt) |
| AU (1) | AU2019364717B2 (lt) |
| BR (1) | BR112021007513A2 (lt) |
| CA (1) | CA3114859A1 (lt) |
| DK (1) | DK3870578T3 (lt) |
| ES (1) | ES2963613T3 (lt) |
| FI (1) | FI3870578T3 (lt) |
| HR (1) | HRP20231306T1 (lt) |
| HU (1) | HUE064111T2 (lt) |
| IL (1) | IL282330B1 (lt) |
| LT (1) | LT3870578T (lt) |
| MX (1) | MX2021004566A (lt) |
| PH (1) | PH12021550872A1 (lt) |
| PL (1) | PL3870578T3 (lt) |
| PT (1) | PT3870578T (lt) |
| RS (1) | RS64836B1 (lt) |
| SG (1) | SG11202103253YA (lt) |
| SI (1) | SI3870578T1 (lt) |
| WO (1) | WO2020084300A1 (lt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA126950C2 (uk) | 2018-08-20 | 2023-02-22 | Янссен Фармацевтика Нв | Інгібітори міжбілкової взаємодії keap1-nrf2 |
| PL3870578T3 (pl) | 2018-10-22 | 2024-03-04 | C4X Discovery Limited | Związki terapeutyczne |
| GB202005852D0 (en) * | 2020-04-22 | 2020-06-03 | C4X Discovery Ltd | Therapeutic compounds |
| GB202005863D0 (en) * | 2020-04-22 | 2020-06-03 | C4X Discovery Ltd | Therapeutic compounds |
| CN114507181B (zh) * | 2020-11-17 | 2024-03-26 | 中国医学科学院药物研究所 | 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用 |
| WO2023073364A1 (en) | 2021-10-25 | 2023-05-04 | C4X Discovery Limited | Tetrahydroisoquinoline compounds that are keap1 binders |
| AR128216A1 (es) * | 2022-01-07 | 2024-04-10 | Chugai Pharmaceutical Co Ltd | Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0330360B1 (en) * | 1988-02-19 | 1993-12-01 | SmithKline Beecham Farmaceutici S.p.A. | 1,2,3,4-Tetrahydroisoquinolines, processes for their preparation, and their use as kappa-receptor agonists |
| PT89780A (pt) | 1988-02-23 | 1989-10-04 | Glaxo Group Ltd | Processo para a preparacao de derivados da tetrahidroisoquinolina |
| US5389638A (en) | 1993-09-10 | 1995-02-14 | Abbott Laboratories | Tetrahydroisoquinolines as alpha-2 antagonists and biogenic amine uptake inhibitors |
| WO1998040385A1 (en) | 1997-03-07 | 1998-09-17 | Novo Nordisk A/S | 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE |
| CA2284732C (en) | 1997-04-07 | 2008-06-17 | Georgetown University | Analogs of cocaine |
| EP1113007A1 (en) | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| PE20040609A1 (es) | 2002-11-01 | 2004-10-29 | Takeda Pharmaceutical | Compuestos heterociclicos aromaticos como promotores de un factor neurotrofico |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| CN102007101A (zh) | 2007-11-30 | 2011-04-06 | 生物区科学管理控股有限公司 | 作为抗菌剂的四氢-异喹啉ppat抑制剂 |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009105746A2 (en) | 2008-02-22 | 2009-08-27 | University Of South Florida | Triazoles and processes for producing the same |
| MX2011004125A (es) | 2008-10-21 | 2011-05-19 | Metabolex Inc | Agonistas del receptor gpr120 de arilo y usos de los mismos. |
| US8367700B2 (en) | 2008-12-17 | 2013-02-05 | Gruenenthal Gmbh | Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators |
| WO2012083866A1 (en) | 2010-12-22 | 2012-06-28 | The Hong Kong Polytechnic University | Quinoline derivatives as anti-cancer agents |
| ES2699226T3 (es) * | 2011-10-14 | 2019-02-08 | Bristol Myers Squibb Co | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa |
| US20140256767A1 (en) * | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| CN103450079B (zh) * | 2013-08-14 | 2015-07-29 | 中国药科大学 | 四氢异喹啉羟基衍生物、其制备方法及其医药用途 |
| US10647679B2 (en) | 2015-03-15 | 2020-05-12 | Emory University | N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto |
| US20180179167A1 (en) | 2015-06-15 | 2018-06-28 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 REGULATORS |
| AR110590A1 (es) * | 2016-12-27 | 2019-04-10 | Biogen Ma Inc | Activador de nrf2 |
| JP2020097526A (ja) | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
| US20200163966A1 (en) | 2017-06-28 | 2020-05-28 | The Regents Of The University Of California | Methods and compositions for treating melanoma |
| US20210283265A1 (en) | 2018-04-20 | 2021-09-16 | Design Therapeutics, Inc. | Methods and compounds for the treatment of genetic disease |
| US20210284629A1 (en) | 2018-05-09 | 2021-09-16 | Design Therapeutics, Inc. | Methods and compounds for the treatment of genetic disease |
| PL3870578T3 (pl) | 2018-10-22 | 2024-03-04 | C4X Discovery Limited | Związki terapeutyczne |
| WO2020210229A1 (en) | 2019-04-08 | 2020-10-15 | Dana-Farber Cancer Institute, Inc. | Degraders of kelch-like ech-associated protein 1 (keap1) |
| CN112409331B (zh) | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| GB202005863D0 (en) | 2020-04-22 | 2020-06-03 | C4X Discovery Ltd | Therapeutic compounds |
| GB202005852D0 (en) | 2020-04-22 | 2020-06-03 | C4X Discovery Ltd | Therapeutic compounds |
-
2019
- 2019-10-22 PL PL19795615.4T patent/PL3870578T3/pl unknown
- 2019-10-22 MX MX2021004566A patent/MX2021004566A/es unknown
- 2019-10-22 FI FIEP19795615.4T patent/FI3870578T3/fi active
- 2019-10-22 DK DK19795615.4T patent/DK3870578T3/da active
- 2019-10-22 HU HUE19795615A patent/HUE064111T2/hu unknown
- 2019-10-22 IL IL282330A patent/IL282330B1/en unknown
- 2019-10-22 EP EP23191389.8A patent/EP4252755A3/en active Pending
- 2019-10-22 KR KR1020217015269A patent/KR20210080474A/ko not_active Application Discontinuation
- 2019-10-22 PT PT197956154T patent/PT3870578T/pt unknown
- 2019-10-22 SG SG11202103253YA patent/SG11202103253YA/en unknown
- 2019-10-22 JP JP2021546488A patent/JP7561742B2/ja active Active
- 2019-10-22 EP EP19795615.4A patent/EP3870578B1/en active Active
- 2019-10-22 CA CA3114859A patent/CA3114859A1/en active Pending
- 2019-10-22 CN CN201980071533.XA patent/CN112996785A/zh active Pending
- 2019-10-22 AU AU2019364717A patent/AU2019364717B2/en active Active
- 2019-10-22 WO PCT/GB2019/053012 patent/WO2020084300A1/en active Application Filing
- 2019-10-22 BR BR112021007513-5A patent/BR112021007513A2/pt unknown
- 2019-10-22 ES ES19795615T patent/ES2963613T3/es active Active
- 2019-10-22 LT LTEPPCT/GB2019/053012T patent/LT3870578T/lt unknown
- 2019-10-22 SI SI201930662T patent/SI3870578T1/sl unknown
- 2019-10-22 RS RS20231069A patent/RS64836B1/sr unknown
- 2019-10-22 US US17/287,942 patent/US12098148B2/en active Active
- 2019-10-22 HR HRP20231306TT patent/HRP20231306T1/hr unknown
-
2021
- 2021-04-19 PH PH12021550872A patent/PH12021550872A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL282330B1 (en) | 2024-09-01 |
| JP2022514437A (ja) | 2022-02-10 |
| EP3870578A1 (en) | 2021-09-01 |
| KR20210080474A (ko) | 2021-06-30 |
| PL3870578T3 (pl) | 2024-03-04 |
| DK3870578T3 (da) | 2023-11-13 |
| HUE064111T2 (hu) | 2024-02-28 |
| EP3870578B1 (en) | 2023-08-16 |
| BR112021007513A2 (pt) | 2021-07-27 |
| CN112996785A (zh) | 2021-06-18 |
| US12098148B2 (en) | 2024-09-24 |
| AU2019364717A1 (en) | 2021-06-03 |
| JP7561742B2 (ja) | 2024-10-04 |
| PH12021550872A1 (en) | 2021-12-06 |
| SI3870578T1 (sl) | 2024-02-29 |
| EP4252755A2 (en) | 2023-10-04 |
| RS64836B1 (sr) | 2023-12-29 |
| ES2963613T3 (es) | 2024-04-01 |
| HRP20231306T1 (hr) | 2024-02-02 |
| WO2020084300A1 (en) | 2020-04-30 |
| FI3870578T3 (fi) | 2023-11-03 |
| SG11202103253YA (en) | 2021-05-28 |
| IL282330A (en) | 2021-05-31 |
| CA3114859A1 (en) | 2020-04-30 |
| EP4252755A3 (en) | 2023-11-08 |
| US20220002286A1 (en) | 2022-01-06 |
| PT3870578T (pt) | 2023-11-15 |
| MX2021004566A (es) | 2021-06-08 |
| AU2019364717B2 (en) | 2023-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201820166D0 (en) | Therapeutic agents | |
| GB201820165D0 (en) | Therapeutic agents | |
| IL282794A (en) | therapeutic method | |
| GB201804255D0 (en) | Macrophage-based therapy | |
| IL282330A (en) | therapeutic compounds | |
| GB201805816D0 (en) | Therapeutic agents | |
| GB201601703D0 (en) | Therapeutic compounds | |
| GB201819853D0 (en) | Therapy | |
| GB201716942D0 (en) | Therapeutic compounds | |
| GB201808150D0 (en) | Therapeutic compounds | |
| GB201908885D0 (en) | Therapeutic compounds | |
| GB201817385D0 (en) | Therapy | |
| GB201818579D0 (en) | New therapy | |
| GB201814036D0 (en) | New therapy | |
| GB201911580D0 (en) | Therapeutic compounds | |
| GB201911574D0 (en) | Therapeutic compounds | |
| GB201907813D0 (en) | Therapeutic compounds | |
| GB201903599D0 (en) | Therapeutic compounds | |
| GB201903597D0 (en) | Therapeutic compounds | |
| GB201807147D0 (en) | Therapeutic combination | |
| GB201820895D0 (en) | Therapy | |
| GB201814038D0 (en) | Ilven therapy | |
| GB201712395D0 (en) | Therapeutic compounds | |
| GB201712388D0 (en) | Therapeutic compounds | |
| GB201712390D0 (en) | Therapeutic compounds |